US3060165A - Preparation of toxic ricin - Google Patents

Preparation of toxic ricin Download PDF

Info

Publication number
US3060165A
US3060165A US3060165DA US3060165A US 3060165 A US3060165 A US 3060165A US 3060165D A US3060165D A US 3060165DA US 3060165 A US3060165 A US 3060165A
Authority
US
United States
Prior art keywords
ricin
toxic
solution
precipitation
cake
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
Publication date
Application granted granted Critical
Publication of US3060165A publication Critical patent/US3060165A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23JPROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
    • A23J1/00Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites
    • A23J1/14Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from leguminous or other vegetable seeds; from press-cake or oil-bearing seeds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants

Definitions

  • This invention relates to the method of preparing toxic llClIl.
  • Ricin is a protoplasmic poison prepared from castor beans after the extraction of castor oil therefrom. It is most effective as a poison when injected intravenously or inhaled, the latter requiring extreme comminution and small particle size to be effective. It is believed that the toxic action is catalytic rather than stoichiometric which probably accounts for the high toxicity of the agent.
  • ricin Because of its relative instability, ricin must be handled with extreme care. In neutral aqueous solution it is stable only up to 60-75 C., and in solid form up to 100110 0, although for short exposures, temperatures up to 130 may be tolerated. It is sensitive to acids, alkalis and halogen and may also be inactivated by mechanical working such as grinding or pulverizing. These factors are of great importance in developing a satisfactory method for preparing the material.
  • the castor beans are first ground and pressed to remove most of the oil.
  • the pressed cake still retains about 15% oil and this may be removed by means of solvents which will extract an additional 150 pounds of oil per ton of beans and reduce the oil retained in the cake to a little over 1%.
  • solvent extraction it is important to prevent detoxification of the protein during the solvent removal step. If residual solvent is removed from the ground beans by blowing with steam, considerable detoxification results. Blowing with nitrogen efiectively prevents detoxification but is expensive when carried out on a large scale.
  • the pressed cake or pomace is extracted by agitating with water at a pH of 3.8101 at 25 C. which removes substantially all of the toxic protein.
  • the extraction process is operative within a pH range of about 3 to 4.5 although the preferred range is about 3.5 to 4.,
  • the optimum operating point is a pH of 3.8-1.1, as indicated above.
  • a careful pH control is essential in order that as much non-toxic protein as possible may be eliminated and also that the filtration rate may be held at a satisfactory value.
  • Either HCl or H 80 may be used to get the desired pH for the extraction water, but H 50 is preferred due to its lower corrosion rate and ease of handling in concentrated form.
  • the acid should be used in reasonably dilute form to prevent undue local concentrations during its addition. A 5% concentration is satisfactory.
  • the slurry is filtered using either a conventional recessed plate filter or a continuous string discharge vacuum filter. With the latter about 7% of filter aid, based on meal weight, was found necessary for satisfactory filtration.
  • the filtrate from the water extraction step which contains the ricin, was treated with a 16.7% solution of Na SO to precipitate the protein.
  • This solution is com- "ice posed of 20 pounds of salt in 100 pounds of water and the amount used was such that the salt content equalled 20% of the filtrate weight.
  • This amount and concentration of salt solution was about optimum considering the factors of cost and toxin recovery. Somewhat higher concentrations and larger amounts of solution can be used, however.
  • the precipitation process is not limited to the use of Na SO since a saturated solution of NaCl can be used successfully, but Na SO solution gives better nitrogen fractionation, more rapid precipitation, and can be operated under wider pH limits. It is desirable to raise the pH to about 7-8 before precipitation as this gives better ecovery and greater non-toxic nitrogen removal.
  • the pH was raised to this value by using NaOH or Na CO the latter being preferred.
  • the base used was quite dilute in order to prevent detoxification due to high local concentrations in the solution. A 5% solution of NaOH was used, whereas with Na CO a 12% solution was preferred. In general, this higher pH during precipitation gave a greater non-toxic nitrogen fractionation and at the same time maintained the toxin loss at less than 2%.
  • the slurry was filtered using from 1 to 4% filter aid, based on slurry weight, for satisfactory filtration; the amount of filter aid needed being dependent on the type of press used. Washing the filter cake with Na SO solution removed additional non-toxic nitrogen which is desirable. In this washing step a 16.7% solution of Na SO was again used. This washing step removed an additional 15% of non-toxic nitrogen from the cake.
  • the filter cake which contains the ricin in combination with the Na SO may be dried and slurried with CCL, to separate the ricin by flotation. Separation of the ricin after a single precipitation and washing step is possible, but it is preferred to carry the process through an additional extraction and precipitation step. This is accomplished by slurrying the filter cake in three times its weight of water and the pH of the slurry is again brought to 3.8:.1 by means of 5% H The slurry is filtered and a second precipitation is brought about by adding Na SO solution. Although pH control here is not wholly essential it is advantageous to bring the pH to approximate neutrality by adding 12% Na CO A precipitation time of 45 minutes was necessary to obtain complete removal of the toxin.
  • the ricin-Na SO precipitate was dried at about 50 to 60 C. on a hot air tray dryer.
  • the dried product was ground to pass a 40 mesh screen and agitated with 5 times its weight of CCl.;, which served the separate the ricin from the Na SO by flotation. After settling, the ricin was skimmed off the top. This reduced the Na SO content of the mixture from a previous 40 to 50% down to 15 to 18%. About 1 to 2% of nitrogen remained in the Na SO salt which could then be used for subsequent precipitations.
  • Spray drying proved to be an even better method of securing a reasonably small particle size. Best results Were achieved by using a solution having about 20% solids, an inlet temperature of 150 C. and an atomizing air pressure of 150 to 180 psi. The particle size secured was 6 to 8 mu.
  • the best means of securing a small particle size was by air grinding. This was carried out in an apparatus having a chamber with conical top and bottom. The material to be ground has been fed into this chamber and is withdrawn from the bottom and forced back into the center of the chamber tangentially through a venturi. Compressed air of about 100 psi. was fed to the venturi to provide the grinding force. The fines are drawn off the top and the large particles settle to the bottom to be recirculated and reground. This process produced particles having a mass median diameter of 2.5 to 3.5 mu.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Botany (AREA)
  • Processing Of Solid Wastes (AREA)

Description

Oct. 23, 1962 H. L. CRAIG ETAL 3,060,165
PREPARATION OF TOXIC RICIN Filed July 3, 1952 LSlurry with waterI pH of 3.8 sou using 5% u so,
LPrecipitate with N 80 pH of 7 using l2% Na,CO,
l Wash filter cake with |6.7% M0 80 I Single extraction Wash solution Extract with wateri pH of 3.8#O.l using H 80 iii Precipitate with Na IpH of 7 using i2% Na ()0 [E'E l Wash filter cake with l6.7% No.80 I
Wash solution Grind cake to 40 mesh Slurry with CCI.
| Settle and skim oft Ricin i Settled M0 reuse I N VEN TORS Harry L. Craig 0. h. A/derks Alsop/l H. 00min Sally h. Die/re 0h affe L. Karel BY 4 14 W ATTORNEY Dry and grind States. ate
This invention relates to the method of preparing toxic llClIl.
Ricin is a protoplasmic poison prepared from castor beans after the extraction of castor oil therefrom. It is most effective as a poison when injected intravenously or inhaled, the latter requiring extreme comminution and small particle size to be effective. It is believed that the toxic action is catalytic rather than stoichiometric which probably accounts for the high toxicity of the agent.
Because of its relative instability, ricin must be handled with extreme care. In neutral aqueous solution it is stable only up to 60-75 C., and in solid form up to 100110 0, although for short exposures, temperatures up to 130 may be tolerated. It is sensitive to acids, alkalis and halogen and may also be inactivated by mechanical working such as grinding or pulverizing. These factors are of great importance in developing a satisfactory method for preparing the material.
Although ricin has been prepared in crystalline condition in the laboratory in small quantities, it becomes necessary, for purposes of toxicological warfare, to prepare relatively large quantities in a high state of purity. This necessitates that as much as possible of the non-toxic material present be removed in the process.
In preparing the protein material, the castor beans are first ground and pressed to remove most of the oil. The pressed cake still retains about 15% oil and this may be removed by means of solvents which will extract an additional 150 pounds of oil per ton of beans and reduce the oil retained in the cake to a little over 1%. In the event that the expressing step is supplemented by solvent extraction, it is important to prevent detoxification of the protein during the solvent removal step. If residual solvent is removed from the ground beans by blowing with steam, considerable detoxification results. Blowing with nitrogen efiectively prevents detoxification but is expensive when carried out on a large scale.
After the oil has been removed, the pressed cake or pomace is extracted by agitating with water at a pH of 3.8101 at 25 C. which removes substantially all of the toxic protein. The extraction process is operative within a pH range of about 3 to 4.5 although the preferred range is about 3.5 to 4., The optimum operating point is a pH of 3.8-1.1, as indicated above. A careful pH control is essential in order that as much non-toxic protein as possible may be eliminated and also that the filtration rate may be held at a satisfactory value. Either HCl or H 80 may be used to get the desired pH for the extraction water, but H 50 is preferred due to its lower corrosion rate and ease of handling in concentrated form. The acid should be used in reasonably dilute form to prevent undue local concentrations during its addition. A 5% concentration is satisfactory.
Following the extraction, the slurry is filtered using either a conventional recessed plate filter or a continuous string discharge vacuum filter. With the latter about 7% of filter aid, based on meal weight, was found necessary for satisfactory filtration.
The filtrate from the water extraction step, which contains the ricin, was treated with a 16.7% solution of Na SO to precipitate the protein. This solution is com- "ice posed of 20 pounds of salt in 100 pounds of water and the amount used was such that the salt content equalled 20% of the filtrate weight. This amount and concentration of salt solution was about optimum considering the factors of cost and toxin recovery. Somewhat higher concentrations and larger amounts of solution can be used, however.
The precipitation process is not limited to the use of Na SO since a saturated solution of NaCl can be used successfully, but Na SO solution gives better nitrogen fractionation, more rapid precipitation, and can be operated under wider pH limits. It is desirable to raise the pH to about 7-8 before precipitation as this gives better ecovery and greater non-toxic nitrogen removal. The pH was raised to this value by using NaOH or Na CO the latter being preferred. The base used was quite dilute in order to prevent detoxification due to high local concentrations in the solution. A 5% solution of NaOH was used, whereas with Na CO a 12% solution was preferred. In general, this higher pH during precipitation gave a greater non-toxic nitrogen fractionation and at the same time maintained the toxin loss at less than 2%.
After precipitation, the slurry was filtered using from 1 to 4% filter aid, based on slurry weight, for satisfactory filtration; the amount of filter aid needed being dependent on the type of press used. Washing the filter cake with Na SO solution removed additional non-toxic nitrogen which is desirable. In this washing step a 16.7% solution of Na SO was again used. This washing step removed an additional 15% of non-toxic nitrogen from the cake.
After filtration the filter cake, which contains the ricin in combination with the Na SO may be dried and slurried with CCL, to separate the ricin by flotation. Separation of the ricin after a single precipitation and washing step is possible, but it is preferred to carry the process through an additional extraction and precipitation step. This is accomplished by slurrying the filter cake in three times its weight of water and the pH of the slurry is again brought to 3.8:.1 by means of 5% H The slurry is filtered and a second precipitation is brought about by adding Na SO solution. Although pH control here is not wholly essential it is advantageous to bring the pH to approximate neutrality by adding 12% Na CO A precipitation time of 45 minutes was necessary to obtain complete removal of the toxin. In filtering out the precipitate, no filter aid was used and the filter cake was washed with Na SO solution on the filter whereby an additional amount of nontoxic nitrogen was removed from the cake. This washing was effective only the first time and repeated washings had little effect in removing further non-toxic nitrogen.
The ricin-Na SO precipitate was dried at about 50 to 60 C. on a hot air tray dryer. The dried product was ground to pass a 40 mesh screen and agitated with 5 times its weight of CCl.;, which served the separate the ricin from the Na SO by flotation. After settling, the ricin was skimmed off the top. This reduced the Na SO content of the mixture from a previous 40 to 50% down to 15 to 18%. About 1 to 2% of nitrogen remained in the Na SO salt which could then be used for subsequent precipitations.
The final precipitation produced a particle size of 1-2 mu. On drying the wet cake, however, the ricin cemented together forming larger particles. These could not be broken down to their original size by ordinary grinding methods and since a very fine particle size was necessary in order that the product might be used as a toxic weapon, it was thought desirable to seek some method to prevent the agglomeration or cementing process that took place on drying.
To attempt to affect this result, physical conditions prevailing under the precipitation process were changed.
This included changing the temperature of precipitation and the rate of agitation. Other changes included precipitation with ony partial saturation of Na SO and the use of wetting and seeding agents. None of these expedients produced any significant improvement in particle size.
Ordinary dry ball and hammer milling of the dried ricin produced considerable detoxifiiation perhaps due to the generation of excess heat. The use of CCl slurry plus the use of low temperature and low moisture content of the ricin reduced detoxification during ball milling.
Spray drying proved to be an even better method of securing a reasonably small particle size. Best results Were achieved by using a solution having about 20% solids, an inlet temperature of 150 C. and an atomizing air pressure of 150 to 180 psi. The particle size secured was 6 to 8 mu.
The best means of securing a small particle size was by air grinding. This was carried out in an apparatus having a chamber with conical top and bottom. The material to be ground has been fed into this chamber and is withdrawn from the bottom and forced back into the center of the chamber tangentially through a venturi. Compressed air of about 100 psi. was fed to the venturi to provide the grinding force. The fines are drawn off the top and the large particles settle to the bottom to be recirculated and reground. This process produced particles having a mass median diameter of 2.5 to 3.5 mu.
Numerous variations are possible in the several steps of the process commencing with the water extraction and precipitation which may be a single or multiple step. Although a single extraction step can be used, as indicated before, some process modifications are necessary for its successful operation on a plant scale. Double extraction proved to be quite efiicien-t but additional steps beyond the second extraction step were not found necessary.
The drawing is self-descriptive and shows the various steps of the process described.
We claim:
1. In a method of preparing toxic ricin from castor beans comprising slurrying an expressed castor bean cake with water to remove the water soluble ricin and precipitating the ricin from the filtrate, the further steps which include slurrying the precipitate with CCl and separating the ricin by flotation.
2. A process in accordance with claim 1 in which the precipitate is dried prior to slurrying.
References Cited in the file of this patent J. Gen. Physiol, vol. 32 (1948), pages 25-31.

Claims (1)

1.IN A METHOD OF PREPARING TOXIC RICIN FROM CASTOR BEANS COMPRISING SLURRYING AN EXPRESSED CASTOR BEAN CAKE WITH WATER TO REMOVE THE WATER SOLUBLE RICIN AND PRECIPI-TATING THE RICIN FROM THE FILTRATE, THE FURTHER STEPS WHICH INCLUDE SLURRYING THE PRECIPITATE WITH CC14 AND SEPARATING THE RICIN BY FLOTATION.
US3060165D Preparation of toxic ricin Expired - Lifetime US3060165A (en)

Publications (1)

Publication Number Publication Date
US3060165A true US3060165A (en) 1962-10-23

Family

ID=3451002

Family Applications (1)

Application Number Title Priority Date Filing Date
US3060165D Expired - Lifetime US3060165A (en) Preparation of toxic ricin

Country Status (1)

Country Link
US (1) US3060165A (en)

Cited By (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4459287A (en) * 1979-11-09 1984-07-10 Eisai Co., Ltd. Immunopotentiator containing recin
US4985541A (en) * 1987-04-10 1991-01-15 Zymogenetics, Inc. Novel cytotoxic protein
WO2005052006A2 (en) 2003-11-25 2005-06-09 The Government Of The United States, As Represented By The Secretary Of Health And Human Services Mutated anti-cd22 antibodies and immunoconjugates
EP2011801A1 (en) 1999-05-27 2009-01-07 Government of the United States as represented by the Secretary, Department of Health and Human Services Immunoconjugates having high binding affinity
WO2009099961A2 (en) 2008-01-31 2009-08-13 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Engineered antibody constant domain molecules
WO2012015912A1 (en) 2010-07-30 2012-02-02 Medimmune, Llc Method for purifying active polypeptides or immunocojugates
WO2013034660A1 (en) 2011-09-09 2013-03-14 Medimmune Limited Anti-siglec-15 antibodies and uses thereof
WO2013039916A1 (en) 2011-09-12 2013-03-21 The United States Of America, Represented By The Secretary, Dept. Of Health And Human Services Compositions for and methods of treatment and enhanced detection of non-pituitary tumors
WO2013138643A1 (en) 2012-03-16 2013-09-19 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Soluble engineered monomeric fc
WO2015069922A2 (en) 2013-11-06 2015-05-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Alk antibodies, conjugates, and chimeric antigen receptors, and their use
WO2016019280A1 (en) 2014-07-31 2016-02-04 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Human monoclonal antibodies against epha4 and their use
WO2016201394A1 (en) 2015-06-12 2016-12-15 Miltenyi Biotec Technology, Inc. Method to treat cancer with engineered t-cells
WO2017062952A1 (en) 2015-10-09 2017-04-13 Miltenyi Biotec Technology, Inc. Chimeric antigen receptors and methods of use
WO2018045325A1 (en) 2016-09-02 2018-03-08 Lentigen Technology, Inc. Compositions and methods for treating cancer with duocars
WO2018129524A1 (en) 2017-01-09 2018-07-12 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-mesothelin immunotherapy
WO2018175988A1 (en) 2017-03-24 2018-09-27 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-cd33 immunotherapy
WO2019028051A1 (en) 2017-07-31 2019-02-07 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-cd19/cd20 immunotherapy
WO2019055842A1 (en) 2017-09-15 2019-03-21 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-cd19 immunotherapy
WO2019079249A1 (en) 2017-10-16 2019-04-25 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-cd22 immunotherapy
EP3494992A1 (en) 2012-12-20 2019-06-12 Medimmune, LLC Refolding and purification of moxetumomab pasudotox
WO2019126464A2 (en) 2017-12-20 2019-06-27 Lentigen Technology, Inc. Compositions and methods for treating hiv/aids with immunotherapy
EP3620470A1 (en) 2013-10-11 2020-03-11 The United States of America, as represented by The Secretary, Department of Health and Human Services Tem8 antibodies and their use
WO2020061498A1 (en) 2018-09-20 2020-03-26 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-cd123 immunotherapy
WO2020069184A2 (en) 2018-09-26 2020-04-02 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-cd19/cd22 immunotherapy
WO2020113108A1 (en) 2018-11-30 2020-06-04 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-cd38 immunotherapy
WO2020181164A1 (en) 2019-03-06 2020-09-10 Lentigen Technology, Inc. Compositions and methods for treating cancer with self-driving chimeric antigen receptors
WO2020243546A1 (en) 2019-05-30 2020-12-03 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-bcma immunotherapy
WO2021003297A1 (en) 2019-07-02 2021-01-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies that bind egfrviii and their use
WO2021262723A1 (en) 2020-06-22 2021-12-30 Lentigen Technology, Inc. Compositions and methods for treating cancer with tslpr-cd19 or tslpr-cd22 immunotherapy
WO2022099026A1 (en) 2020-11-05 2022-05-12 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-cd19/cd22 immunotherapy
US11590169B1 (en) 2022-03-02 2023-02-28 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-CD123 immunotherapy
WO2023168243A1 (en) 2022-03-02 2023-09-07 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-cd123 immunotherapy
WO2024026107A2 (en) 2022-07-28 2024-02-01 Lentigen Technology, Inc. Chimeric antigen receptor therapies for treating solid tumors
WO2024044743A1 (en) 2022-08-26 2024-02-29 Lentigen Technology, Inc. Compositions and methods for treating cancer with fully human anti-cd20/cd19 immunotherapy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None *

Cited By (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4459287A (en) * 1979-11-09 1984-07-10 Eisai Co., Ltd. Immunopotentiator containing recin
US4985541A (en) * 1987-04-10 1991-01-15 Zymogenetics, Inc. Novel cytotoxic protein
EP2011801A1 (en) 1999-05-27 2009-01-07 Government of the United States as represented by the Secretary, Department of Health and Human Services Immunoconjugates having high binding affinity
WO2005052006A2 (en) 2003-11-25 2005-06-09 The Government Of The United States, As Represented By The Secretary Of Health And Human Services Mutated anti-cd22 antibodies and immunoconjugates
EP2204385A1 (en) 2003-11-25 2010-07-07 The Government Of U.S.A, As Represented By Secretary, Department of Health and Human Sevices Pseudomonas exotoxin A mutants and uses thereof
EP2594584A1 (en) 2008-01-31 2013-05-22 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Engineered constant domain molecule of an antibody
WO2009099961A2 (en) 2008-01-31 2009-08-13 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Engineered antibody constant domain molecules
US11136396B2 (en) 2010-07-30 2021-10-05 Medimmune Limited Method for purifying active polypeptides or immunoconjugates
EP3434346A1 (en) 2010-07-30 2019-01-30 Medimmune, LLC Purified active polypeptides or immunoconjugates
US10556955B2 (en) 2010-07-30 2020-02-11 Medimmune Limited Method for purifying active polypeptides or immunoconjugates
WO2012015912A1 (en) 2010-07-30 2012-02-02 Medimmune, Llc Method for purifying active polypeptides or immunocojugates
EP3797847A1 (en) 2010-07-30 2021-03-31 Medlmmune, LLC Purified active polypeptides or immunoconjugates
WO2013034660A1 (en) 2011-09-09 2013-03-14 Medimmune Limited Anti-siglec-15 antibodies and uses thereof
WO2013039916A1 (en) 2011-09-12 2013-03-21 The United States Of America, Represented By The Secretary, Dept. Of Health And Human Services Compositions for and methods of treatment and enhanced detection of non-pituitary tumors
WO2013138643A1 (en) 2012-03-16 2013-09-19 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Soluble engineered monomeric fc
EP3494992A1 (en) 2012-12-20 2019-06-12 Medimmune, LLC Refolding and purification of moxetumomab pasudotox
EP4269421A2 (en) 2013-10-11 2023-11-01 The United States of America, as represented by The Secretary, Department of Health and Human Services Tem8 antibodies and their use
EP3620470A1 (en) 2013-10-11 2020-03-11 The United States of America, as represented by The Secretary, Department of Health and Human Services Tem8 antibodies and their use
WO2015069922A2 (en) 2013-11-06 2015-05-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Alk antibodies, conjugates, and chimeric antigen receptors, and their use
US10934360B2 (en) 2014-07-31 2021-03-02 The Hong Kong University Of Science And Technology Human monoclonal antibodies against EPHA4 and their use
WO2016019280A1 (en) 2014-07-31 2016-02-04 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Human monoclonal antibodies against epha4 and their use
EP3473271A1 (en) 2014-07-31 2019-04-24 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Human monoclonal antibodies against epha4 and their use
WO2016201394A1 (en) 2015-06-12 2016-12-15 Miltenyi Biotec Technology, Inc. Method to treat cancer with engineered t-cells
EP3845557A1 (en) 2015-06-12 2021-07-07 Lentigen Technology, Inc. Method to treat cancer with engineered t-cells
EP4286511A2 (en) 2015-06-12 2023-12-06 Lentigen Technology, Inc. Method to treat cancer with engineered t-cells
US10639329B2 (en) 2015-06-12 2020-05-05 Lentigen Technology, Inc. Method to treat cancer with engineered T-cells
WO2017062952A1 (en) 2015-10-09 2017-04-13 Miltenyi Biotec Technology, Inc. Chimeric antigen receptors and methods of use
EP3660044A1 (en) 2015-10-09 2020-06-03 Miltenyi Biotec Technology, Inc. Chimeric antigen receptors and methods of use
WO2020061194A2 (en) 2016-09-02 2020-03-26 Lentigen Technology, Inc. Compositions and methods for treating cancer with duocars
WO2021102337A1 (en) 2016-09-02 2021-05-27 Lentigen Technology, Inc. Compositions and methods for treating cancer with duocars
WO2018045325A1 (en) 2016-09-02 2018-03-08 Lentigen Technology, Inc. Compositions and methods for treating cancer with duocars
EP4282969A2 (en) 2016-09-02 2023-11-29 Lentigen Technology, Inc. Compositions and methods for treating cancer with duocars
WO2018129524A1 (en) 2017-01-09 2018-07-12 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-mesothelin immunotherapy
EP4183798A1 (en) 2017-01-09 2023-05-24 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-mesothelin immunotherapy
EP3882265A1 (en) 2017-01-09 2021-09-22 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-mesothelin immunotherapy
WO2018175988A1 (en) 2017-03-24 2018-09-27 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-cd33 immunotherapy
WO2019028051A1 (en) 2017-07-31 2019-02-07 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-cd19/cd20 immunotherapy
EP4279086A2 (en) 2017-09-15 2023-11-22 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-cd19 immunotherapy
WO2019055842A1 (en) 2017-09-15 2019-03-21 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-cd19 immunotherapy
EP4279584A2 (en) 2017-10-16 2023-11-22 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-cd22 immunotherapy
WO2019079249A1 (en) 2017-10-16 2019-04-25 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-cd22 immunotherapy
WO2019126464A2 (en) 2017-12-20 2019-06-27 Lentigen Technology, Inc. Compositions and methods for treating hiv/aids with immunotherapy
WO2020061498A1 (en) 2018-09-20 2020-03-26 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-cd123 immunotherapy
WO2020069184A2 (en) 2018-09-26 2020-04-02 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-cd19/cd22 immunotherapy
WO2020113108A1 (en) 2018-11-30 2020-06-04 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-cd38 immunotherapy
WO2020181164A1 (en) 2019-03-06 2020-09-10 Lentigen Technology, Inc. Compositions and methods for treating cancer with self-driving chimeric antigen receptors
US11052112B2 (en) 2019-05-30 2021-07-06 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-BCMA immunotherapy
WO2020243546A1 (en) 2019-05-30 2020-12-03 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-bcma immunotherapy
WO2021003297A1 (en) 2019-07-02 2021-01-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies that bind egfrviii and their use
WO2021262723A1 (en) 2020-06-22 2021-12-30 Lentigen Technology, Inc. Compositions and methods for treating cancer with tslpr-cd19 or tslpr-cd22 immunotherapy
WO2022099026A1 (en) 2020-11-05 2022-05-12 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-cd19/cd22 immunotherapy
WO2023168243A1 (en) 2022-03-02 2023-09-07 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-cd123 immunotherapy
US11590169B1 (en) 2022-03-02 2023-02-28 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-CD123 immunotherapy
WO2024026107A2 (en) 2022-07-28 2024-02-01 Lentigen Technology, Inc. Chimeric antigen receptor therapies for treating solid tumors
WO2024044743A1 (en) 2022-08-26 2024-02-29 Lentigen Technology, Inc. Compositions and methods for treating cancer with fully human anti-cd20/cd19 immunotherapy

Similar Documents

Publication Publication Date Title
US3060165A (en) Preparation of toxic ricin
US5135765A (en) Process for producing protein-rich product, fibrous product and/or vegetable oil from brewer's spent grain
US2881159A (en) Process for isolating soya protein
JPS58501207A (en) Lupine extraction method and equipment
KR20010032859A (en) A method for making a reconstituted tobacco sheet using steam exploded tobacco
US4100305A (en) Method of making an improved coffee volatiles concentrate
CA1129176A (en) Process of recovering potassium chloride
US3408374A (en) Process for the treatment of vegetable materials
US2758927A (en) Process of making soluble coffee concentrate
CN108948124A (en) A kind of preparation method of Tea Saponin
US2044769A (en) Process for preparing zein
US4151310A (en) Soybean protein extract
JPS5843745A (en) Extraction of roasted ground coffee
US2811411A (en) Method of processing monazite sand
GB2078703A (en) Producing active silica
US4191336A (en) Process for recovering magnetite from fly ash
US4128637A (en) Process for producing thymosin
DE2704017A1 (en) PROCESS FOR PRODUCING SOLUBLE COFFEE
AU667635B2 (en) Process for the recovery of silver by flotation from the residue from the wet extraction of zinc
US3908033A (en) Preparation of soluble coffee
US3941835A (en) Recovery of L-Dopa from R-dopa containing materials
US2547980A (en) Method for detoxifying castor bean proteins
US2593528A (en) Mucilaginous materials from flaxseed
US2460627A (en) Process fob the isolation of
JP3315418B2 (en) Instant coffee production method